Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized controlled, phase II clinical trial, aiming at
giving a comparison of Sintilimab and Pembrolizumab in stage IIIB-IV NSCLC patients at
first-line treatment setting.